Search research articles
Contact Us
Filters
Showing results (341-350 of 393) with videos related to
Page
of 40
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Breelyn A Wilky, Gary K Schwartz, Michael S Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
Yoon-Koo Kang, Suzanne George, Robin L Jones, et al.
Sarcoma
|
November 16, 2017
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors
Christine S Higham, Seth M Steinberg, Eva Dombi, et al.
Oncoimmunology
|
December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.
Journal for Immunotherapy of Cancer
|
September 1, 2021
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes
Brett A Schroeder, Natalie A LaFranzo, Bonnie J LaFleur, et al.
Sarcoma
|
May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
Kristin Baird, John Glod, Seth M Steinberg, et al.
JAMA
|
April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial
William D Tap, Andrew J Wagner, Patrick Schöffski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial
Patrick Schöffski, Roberta Sanfilippo, Javier Martín-Broto, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy
Karan Kohli, Lu Yao, Theodore Scott Nowicki, et al.
Page
of 40
Search research articles
Search
Showing results (341-350 of 393) with videos related to
Sort By:
Page
of 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Breelyn A Wilky, Gary K Schwartz, Michael S Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
Yoon-Koo Kang, Suzanne George, Robin L Jones, et al.
Sarcoma
|
November 16, 2017
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors
Christine S Higham, Seth M Steinberg, Eva Dombi, et al.
Oncoimmunology
|
December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.
Journal for Immunotherapy of Cancer
|
September 1, 2021
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes
Brett A Schroeder, Natalie A LaFranzo, Bonnie J LaFleur, et al.
Sarcoma
|
May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
Kristin Baird, John Glod, Seth M Steinberg, et al.
JAMA
|
April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial
William D Tap, Andrew J Wagner, Patrick Schöffski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial
Patrick Schöffski, Roberta Sanfilippo, Javier Martín-Broto, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy
Karan Kohli, Lu Yao, Theodore Scott Nowicki, et al.
Page
of 40